Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q

International Journal of Cancer

Volumn 104, Issue 1, 2003, Pages 73-84

  Stone, Brad ^a   Schummer, Michél ^b   Paley, Pamela J ^c   Thompson, Lucas ^a   Stewart, Julie ^a   Ford, Molly ^a   Crawford, Meghan ^a   Urban, Nicole ^d   O'Briant, Kathy ^d   Nelson, Brad H ^a,c,d  

^a Virginia Mason Research Institute   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Autoantibodv; Ovary; SEREX; Tumor antigen

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); HELICASE; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PROTEIN P53; TUMOR ANTIGEN; UBIQUITIN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SCREENING; CHROMOSOME 17Q; CONTROLLED STUDY; DNA LIBRARY; FEMALE; HOMEOBOX; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; ONCOGENE; ONCOGENE NEU; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0037430144     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10900     Document Type: Article

References (40)

1. Ries LAG, Eisner MPL, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds. SEER cancer statistics review, 1973-1999.
2. Bast RC Jr, Feeney M. Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
3. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-7.
4. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma? Gynecol Oncol 2000;77:347-9.
5. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
6. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr. Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-8.
7. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
8. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
9. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G, Genazzani AR. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999;72:76-81.
10. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang JM, Hsieh LL. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 2001;94:859-63.
11. Warnakulasuriya S, Soussi T, Maher R, Johnson N, Tavassoli M. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol 2000;192:52-7.
12. Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer 1998;78:390-1.
13. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
14. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
15. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Preexistent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
16. Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci USA 2001;98:4060-5.
17. Sahn U, Tureci O, Schmitt H. Cochlovius B, Johannes T. Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
18. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61:5345-8.
19. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B. Contribution of cerbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.
20. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156: 839-47.
21. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238:375-85.
22. Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000;88: 1432-7.
23. Grigolo B, Mazzetti I, Borzi RM, Hickson ID, Fabbri M, Fasano L, Meliconi R, Facchini A. Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin Exp Immunol 1998;114:339-46.
24. Grigolo B, Mazzetti I, Meliconi R, Bazzi S, Scorza R, Candela M, Gabrielli A, Facchini A. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis - association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000;121:539-43.
25. Korneeva I, Bongiovanni AM, Girottra M, Caputo TA, Witkin SS. IgA antibodies to the 27-kDa heat shock protein in the genital tracts of women with gynecologic cancers. Int J Cancer 2000;87:824-8.
26. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97: 4760-5.
27. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187: 265-70.
28. Young SR, Liu WH, Brock JA, Smith ST. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer 1996;16:130-7.
29. Afify AM, Werness, BA, Mark HF. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp Mol Pathol 1999;66:163-9.
30. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A. Kalli K, Keeney G, Roche P, et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 2001; 61:5895-904.
31. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001;169:155-64.
32. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCAI dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94: 61-7.
33. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000;60:5329-33.
34. Knoepfler PS, Sykes DB, Pasillas M, Kamps MP. HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. Oncogene 2001;20:5440-8.
35. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001;21:224-34.
36. Krosl J, Baban S, Krosl G, Rozenfeld S, Largman C, Sauvageau G. Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBXI. Oncogene 1998; 16:3403-12.
37. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286: 531-7.
38. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
39. Kurts C, Klebba I, Davey GM, Koch KM, Miller JF, Heath WR, Floege J. Kidney protection against autoreactive CD8(+) T cells distinct from immunoprivilege and sequestration. Kidney Int 2001; 60:664-71.
40. Zanaboni F, Vergadoro F, Presti M, Gallotti P, Lombardi F, Bolis G. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol 1987;28:61-7.